BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31001799)

  • 1. Expression of Prox1 in Medullary Thyroid Carcinoma Is Associated with Chromogranin A and Calcitonin Expression and with Ki67 Proliferative Index, but Not with Prognosis.
    Saglietti C; La Rosa S; Sykiotis GP; Letovanec I; Bulliard JL; Piana S; Mermod M; Petrova T; Uccella S; Sessa F; Bongiovanni M
    Endocr Pathol; 2019 Jun; 30(2):138-145. PubMed ID: 31001799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROX1 Promotes Secretory Granule Formation in Medullary Thyroid Cancer Cells.
    Ishii J; Yazawa T; Chiba T; Shishido-Hara Y; Arimasu Y; Sato H; Kamma H
    Endocrinology; 2016 Mar; 157(3):1289-98. PubMed ID: 26760117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
    Xu B; Fuchs TL; Ahmadi S; Alghamdi M; Alzumaili B; Bani MA; Baudin E; Chou A; De Leo A; Fagin JA; Ganly I; Glover A; Hartl D; Kanaan C; Khneisser P; Najdawi F; Nigam A; Papachristos A; Repaci A; Spanheimer PM; Solaroli E; Untch BR; Barletta JA; Tallini G; Al Ghuzlan A; Gill AJ; Ghossein RA
    J Clin Oncol; 2022 Jan; 40(1):96-104. PubMed ID: 34731032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
    Zhou Q; Yue S; Cheng Y; Jin J; Xu H
    Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and clinical significance of Ki67 and calcitonin in medullary thyroid carcinoma].
    Feng J; Wang J
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Dec; 28(24):1921-4. PubMed ID: 25895305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
    Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
    Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum calcitonin negative mixed medullary-follicular carcinoma initially diagnosed as medullary thyroid carcinoma by fine-needle aspiration cytology: A case report and review of the literatures.
    Liu Y; Yuan L; Yang D; Jin Y
    Diagn Cytopathol; 2018 Aug; 46(8):690-693. PubMed ID: 29524315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
    Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
    Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
    Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
    Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
    Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
    J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma.
    Nigam A; Xu B; Spanheimer PM; Ganly I; Tuttle RM; Wong RJ; Shaha AR; Ghossein RA; Untch BR
    Thyroid; 2022 Oct; 32(10):1193-1200. PubMed ID: 35950622
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and characterization of a novel cell line of medullary thyroid carcinoma from a dog.
    Okano K; Uematsu Y; Nibe K; Yamashita M; Suzuki S; Uchida K; Ono K; Hirao H
    In Vitro Cell Dev Biol Anim; 2019 Aug; 55(7):559-566. PubMed ID: 31144267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of FoxA1 expression in thyroid tumors.
    Nonaka D
    Hum Pathol; 2017 Jul; 65():217-224. PubMed ID: 28546130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medullary thyroid carcinoma experienced at Kanazawa University Hospital.
    Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Ohtake S; Nakamura S; Ishizaki T
    J Surg Oncol; 1996 Jan; 61(1):27-33. PubMed ID: 8544456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years.
    Jung KY; Kim SM; Yoo WS; Kim BW; Lee YS; Kim KW; Lee KE; Jeong JJ; Nam KH; Lee SH; Hah JH; Chung WY; Yi KH; Park DJ; Youn YK; Sung MW; Cho BY; Park CS; Park YJ; Chang HS
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):587-97. PubMed ID: 26175307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.
    Dottorini ME; Assi A; Sironi M; Sangalli G; Spreafico G; Colombo L
    Cancer; 1996 Apr; 77(8):1556-65. PubMed ID: 8608543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
    Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
    Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
    Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.